celecoxib has been researched along with plumbagin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gowda, R; Robertson, GP; Sharma, A | 1 |
| Gowda, R; Kardos, G; Robertson, GP; Sharma, A; Singh, S | 1 |
2 other study(ies) available for celecoxib and plumbagin
| Article | Year |
|---|---|
Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclins; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; G2 Phase Cell Cycle Checkpoints; Humans; Melanoma; Mice, Nude; Naphthoquinones; Signal Transduction; Skin Neoplasms; STAT3 Transcription Factor; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Celecoxib; Cell Line, Tumor; Cell Survival; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Drug Compounding; Drug Stability; Drug Synergism; Female; Humans; Liposomes; Melanoma; Mice; Nanoparticles; Naphthoquinones; STAT3 Transcription Factor; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |